EBS
NYSE · Biotechnology
Emergent Biosolutions Inc
$6.80
-0.22 (-3.13%)
Open$6.98
Previous Close$7.02
Day High$7.05
Day Low$6.77
52W High$14.06
52W Low$4.36
Volume—
Avg Volume1.24M
Market Cap350.71M
P/E Ratio—
EPS$-3.51
SectorBiotechnology
Analyst Ratings
Buy
7 analysts
Price Target
+298.2% upside
Current
$6.80
$6.80
Target
$27.08
$27.08
$18.81
$27.08 avg
$37.55
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 737.58M | 845.94M | 356.03M |
| Net Income | 52.22M | 53.91M | -80,261,545 |
| Profit Margin | 7.1% | 6.7% | -22.5% |
| EBITDA | 151.90M | 165.51M | -95,339,299 |
| Free Cash Flow | — | — | -67,766,487 |
| Rev Growth | -12.8% | -12.8% | +7.9% |
| Debt/Equity | 1.09 | 1.09 | 0.39 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.48 | +0.20% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $393.16 | +1.95% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.56 | +0.30% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $510.72 | +0.47% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $798.17 | +1.70% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $244.32 | +1.99% | 40.0 | 32.33B |